Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Victory Capital Holdings (VCTR) Recently Broke Out Above the 20-Day Moving Average
Victory Capital Holdings (VCTR) Recently Broke Out Above the 20-Day Moving Average

From a technical perspective, Victory Capital Holdings (VCTR) is looking like an interesting pick, as it just reached a key level of support. VCTR recently overtook the 20-day moving average, and

Is Vanguard Consumer Staples Index Admiral (VCSAX) a Strong Mutual Fund Pick Right Now?
Is Vanguard Consumer Staples Index Admiral (VCSAX) a Strong Mutual Fund Pick Right Now?

Looking for a Large Cap Blend fund? You may want to consider Vanguard Consumer Staples Index Admiral (VCSAX) as a possible option. The fund does not have a Zacks Mutual Fund Rank, though we have

Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?
Why Is Veracyte (VCYT) Up 18.2% Since Last Earnings Report?

A month has gone by since the last earnings report for Veracyte (VCYT). Shares have added about 18.2% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading

Here's Why Veracyte (VCYT) is a Strong Momentum Stock
Here's Why Veracyte (VCYT) is a Strong Momentum Stock

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates

Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?
Veracyte Stock Surges 65.8% in a Year: What's Driving the Rally?

Veracyte’s VCYT shares have surged 65.8% over the past year, showing impressive momentum. It has significantly outperformed the industry’s 4.8% decline and the S&P 500 composite’s 33.1% gain.  

Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?
Is it Worth Retaining Veracyte Stock in Your Portfolio for Now?

Veracyte VCYT is well poised to grow in the upcoming quarters owing to its ongoing sales momentum of Afirma and Decipher Prostate tests. Meanwhile, operational headwinds from macroeconomic pressures

Can Visa's New AR Integration Accelerate Virtual Card Adoption?
Can Visa's New AR Integration Accelerate Virtual Card Adoption?

Visa Inc. V recently expanded its Visa Commercial Solutions Hub or VCS Hub (launched in 2025) by integrating Visa Accounts Receivable Manager (Visa AR Manager) into the platform, giving eligible